TB-500 has been well-tolerated in various research applications, with its endogenous nature (as Thymosin Beta-4) suggesting compatibility with normal physiology
Heres what the clinical evidence shows: Study Scope: 900+ participants across 6 randomized, double-blind, placebo-controlled trials Safety Profile: Indistinguishable from placebo in tolerability assessments Serious Events: Zero serious adverse events attributed to AOD-9604 Withdrawals: No treatment-related discontinuations in any trial Common Effects: Mild headache and minor GI symptoms at rates similar to placebo IGF-1 Impact: No effect on insulin-like growth factor-1 levels Metabolic Safety: No negative impact on glucose metabolism or insulin sensitivity Immunogenicity: Zero participants developed anti-AOD9604 antibodies The following analysis provides complete details on the clinical trial evidence supporting AOD-9604s favorable safety profile
Recovery Support Metabolic Wellness Vitality Momentum MOTS-c Benefits Cellular momentum, built into your rhythm
Tracking Your Vial: A Simple System Once you're injecting weekly from a reconstituted vial, it's easy to lose track of how many doses you've used, what's left, and when the vial expires
Focus on rest and tissue protection
Hudock suggests: People probably warned you about the sleepless nights after baby comes, but trouble sleeping during pregnancy is common, too
